SHP2 Inhibitor ET0038 Monotherapy in Patients With Advanced Solid Tumors

Summary

This is a Phase I, open-label, multi-center, dose-finding study to assess the safety, pharmacokinetics, and preliminary efficacy of ET0038 in patients with advanced solid tumors. It is anticipated that approximately 34 subjects will be enrolled in the dose-escalation phase of the study. ET0038 will be administered orally once daily (QD) in 21-day treatment cycles.

Timeline

Start

2022-11-01

Primary completion

2024-11-01

Completion

2025-05-01

Drugs

Indications